Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Cash & Current Investments (2020 - 2025)

RxSight (RXST) has disclosed Cash & Current Investments for 6 consecutive years, with $228.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments fell 50.16% year-over-year to $228.1 million, compared with a TTM value of $228.1 million through Dec 2025, down 50.16%, and an annual FY2025 reading of $228.1 million, down 50.16% over the prior year.
  • Cash & Current Investments was $228.1 million for Q4 2025 at RxSight, up from $197.9 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $457.7 million in Q4 2024 and bottomed at $81.7 million in Q2 2021.
  • Average Cash & Current Investments over 5 years is $232.8 million, with a median of $228.1 million recorded in 2025.
  • The sharpest move saw Cash & Current Investments tumbled 68.17% in 2024, then skyrocketed 364.51% in 2025.
  • Year by year, Cash & Current Investments stood at $159.3 million in 2021, then rose by 25.38% to $199.8 million in 2022, then rose by 19.87% to $239.5 million in 2023, then skyrocketed by 91.15% to $457.7 million in 2024, then plummeted by 50.16% to $228.1 million in 2025.
  • Business Quant data shows Cash & Current Investments for RXST at $228.1 million in Q4 2025, $197.9 million in Q3 2025, and $227.5 million in Q2 2025.